Degarelix and its therapeutic potential in the treatment of prostate cancer

Christian Doehn
Martin Sommerauer
Dieter Jocham
Department of Urology, University of Lübeck Medical School, Lübeck, Germany

Abstract: Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of patients with prostate cancer in whom hormonal therapy is indicated. Two phase II trials and one phase III have been published as full papers in the literature. In the dose-finding phase II studies an initial dose of 240 mg degarelix sc followed by a monthly injection of 80 mg or 160 mg degarelix sc was sufficient to keep testosterone levels ≤ 0.5 ng/ml. In a phase III trial it was demonstrated that degarelix was not inferior (in terms of testosterone suppression and prostate-specific antigen [PSA] decline) compared to standard hormonal therapy, ie, a GnRH agonist such as leuprolide. In fact, degarelix was associated with a faster testosterone suppression and PSA decline than leuprolide. Adverse events such as injection site reactions (40% vs <1%) and chills (4% vs 0%) were more commonly associated with degarelix. Also, degarelix is currently only available as one-month depot whereas in daily practice three-month depots (of GnRH agonists) are the preferred regimen. However, degarelix was recently approved by the US Food and Drug Administration for the treatment of advanced prostate cancer.

Keywords: prostate cancer, hormonal therapy, GnRH antagonist, degarelix, testosterone, flare

Introduction
Prostate cancer is the most common malignancy in the US and in western Europe with an estimated 186,320 newly diagnosed cases in 2008 in the US and 28,660 men who died of prostate cancer in the US (incidence-mortality ratio of 6.5).1

The therapeutic options available predominantly depend on cancer stage as well as patient age and co-morbidity. In organ-confined prostate cancer the treatment is radical prostatectomy, external beam radiotherapy, or brachytherapy. In this stage of the disease, therapy is with curative intention and patients have an excellent prognosis.2 Active surveillance or watchful waiting are also options in patients with low risk organ-confined prostate cancer (ie, clinical stage T1c-2a and Gleason score 6 and prostate-specific antigen (PSA) less than 10 and less than 33% of prostate biopsies positive for cancer).3 Primary androgen deprivation therapy might also be an option but without curative intention.4 However, androgen deprivation therapy is not regarded as standard in patients with localized prostate cancer.5

In metastatic prostate cancer and/or in patients who are not able to undergo the above treatment options because of their age and/or co-morbidity, the standard of care is androgen deprivation therapy.6 Watchful waiting may also be applied under the latter circumstances.

Huggins first described the effect of castration on prostate cancer in 1941.7 This was the basis for the finding that prostate cancer cells need androgens for their growth. Without the receptor-mediated stimulus of androgens prostate cancer cells undergo apoptosis.8,9 Androgens are synthesized in the testes (95%) and in the adrenal glands (5%). The androgen synthesis underlies a hormonal regulation by the hypothalamic–pituitary–gonadal axis in a negative feedback manner.
Based on these findings, lowering testosterone levels either medically or surgically and/or blockade of the androgen receptor represents the principal mechanism of androgen deprivation therapy of prostate cancer. Surgical castration can be done by bilateral orchiectomy. This is an effective procedure and not associated with relevant complications. The disadvantages are the possible negative psychological effects and the fact that no intermittent androgen deprivation therapy can be applied.

Similar effects can be achieved by suppression of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) with gonadotropin-releasing hormone (GnRH) agonists (eg, buserelin, goserelin, leuproline, triptorelin) that desensitize the pituitary gland. This leads to a suppression of the LH synthesis and secretion followed by decreased stimulus for testosterone synthesis within the testicles. Another medical manipulation of this hormonal regulation can be achieved by blocking the androgen receptor with steroidal antiandrogens (eg, cyproterone acetate) or nonsteroidal antiandrogens (eg, bicalutamide, flutamide). However, the effect from androgen receptor blockade is considered to be less effective compared to LH-releasing hormone (LHRH) antagonists (at least in metastatic disease).

Blocking the GnRH receptor with an antagonist in the pituitary gland is obviously the most logical way to achieve a fast and reversible decrease of LH, FSH, and testosterone without any clinical flare. For a long time, however, GnRH antagonists showed relevant release of histamine from mast cells with acute systemic allergic reactions. Another contraindication for clinical usefulness was limited solubility. Degarelix (Ferring Pharmaceuticals, Kiel, Germany) is the second GnRH antagonist that has been tested in a phase III trial. Degarelix has also proven its potential in achieving testosterone suppression without any evidence of clinical flare. Additionally, no acute systemic allergic reactions were observed in patients treated with degarelix.

This review aims to summarize phase II and III trials on degarelix for the treatment of patients with prostate cancer.

Efficacy
Phase II dose-finding studies
There are four phase II dose-finding studies in the literature. Two of them are only available in abstract form and the remaining are full publications.

Data from a randomized phase II trial were presented by Weston and colleagues at the SIU congress in 2004. In this trial, 129 patients (age 55–87 years) with prostate cancer of all stages who were candidates for androgen deprivation therapy were treated in three different dose regimens between 20 mg and 80 mg (arm A: degarelix 80/80/40 (ie, 80 mg on day 0, 80 mg on day 3, and 40 mg on day 28); arm B: degarelix 80/60/20; arm C: degarelix 40/40/40) administered on day 0, 3, and 28, respectively, and every 28 days thereafter. At baseline the median PSA level was 61 ng/ml. In this study, arm A was the most effective in achieving castration levels. At six-month follow-up 87.5%, 72.2%, and 58.8% of patients in arms A, B, and C had a testosterone ≤0.5 ng/ml.

Results from a phase II multicenter, randomized dose-escalating study testing degarelix in patients with prostate cancer were presented by Tammela and colleagues at the EAU congress in 2005. In this trial, 172 patients (age 48–89 years) with prostate cancer were included. These patients had a baseline median testosterone of 4.16 ng/ml and a median PSA of 38 ng/ml. Patients with metastatic prostate cancer (31%), locally advanced prostate cancer (36%), and localized prostate cancer (26%) were included. Degarelix was administered sc at doses between 120 mg and 320 mg. The concentrations varied between 20 mg/ml and 60 mg/ml. The efficacy could be evaluated in 169 patients at day 3 and day 28 by measurement of testosterone and PSA. Degarelix showed a dose- and concentration-dependent effect. A dose of 240 mg (40 mg/ml) resulted in castration (defined as testosterone ≤0.5 ng/ml) in 96% of the patients and was the most effective regimen.

Two phase II studies have been conducted to evaluate the efficacy of degarelix in different doses regimen in long-term follow-up.

One open label, randomized phase II study with a starting dose of 200 mg degarelix sc and a monthly administration of 60 mg degarelix sc (200/60, arm A) or 80 mg degarelix sc (200/80, arm B) was conducted in North America. In total, 127/176 screened patients with prostate cancer were enrolled. Patients had a median age of 76 years (range 47–93 years). Inclusion criteria were testosterone >2.2 ng/ml, PSA >2 ng/ml, and Eastern Cooperative Oncology Group (ECOG) score of 2 or less.

The primary endpoint was the proportion of patients with serum testosterone ≤0.5 ng/ml at all monthly measurements throughout the entire study period (ie, 12 months) and the proportion of patients with testosterone ≤0.5 ng/ml at all monthly measurements throughout the entire study period for those patients who had a testosterone ≤0.5 ng/ml after one month. Secondary endpoints included:

- The proportion of patients with a testosterone ≤0.5 ng/ml at day 3
- Time to 50% and 90% reduction in PSA
Degarelix in prostate cancer

- Time to PSA progression (defined as PSA increase of 50% or more from nadir and at least 5 ng/ml on two consecutive visits at least two weeks apart)
- Pharmacodynamic parameters such as testosterone, PSA, dihydrotestosterone (DHT), LH, and FSH over time.

There were 23 patients with protocol violations, 16 withdrawals due to inadequate testosterone suppression, six withdrawals due to adverse events, and 18 withdrawals due to other reasons. Therefore, 87/127 patients (69%) completed the study. Arm A comprised of 42 patients and arm B of 45 patients without differences with regard to demographics and baseline characteristics. Median PSA at baseline was 13.4 ng/ml (25th–75th percentile: 6.8–25.7 ng/ml). Median testosterone level at baseline was 4.13 ng/ml (25th–75th percentile: 3.06–5.11 ng/ml). Tumor stages were localized in 43%, locally advanced in 11%, metastatic in 19%, and not classifiable in 28% of patients. The Gleason score was 2–4 in 5%, 5–6 in 32%, and 7–10 in 63% of cases, respectively.

In this study no testosterone surge was observed. At day 3, 89% of all patients had a testosterone $<0.5$ ng/ml without a statistically significant difference between both groups (Table 1). After one month 88% of all patients had a testosterone $<0.5$ ng/ml (93% of patients in arm A compared to 83% of patients in arm B $p = 0.073$). The authors concluded that the starting dose was too low to achieve the predefined efficacy success criterion of 95% of patients with a testosterone level $\leq 0.5$ ng/ml. This was the rationale to test 240 mg as a starting dose in subsequent trials. Only 86% of patients in arm A and 77% of patients in arm B remained with their testosterone $\leq 0.5$ ng/ml during the entire study period ($p =$ not significant, exact $p$ value not given in publication). However, the majority of patients who had a testosterone $\leq 0.5$ ng/ml after one month remained within this range for the entire study period (93% of patients in arm A compared to 98% of patients in arm B; $p = 0.669$). A PSA decline of 50% and 90% was achieved after 14 and 56 days in both treatment groups and a median reduction of 96% was documented after 12 months.

The second study was conducted in Europe and South Africa and screened 216 patients with prostate cancer of whom 189 were randomized and 187 received study medication. Median age was 72 years (range 52–93 years). The inclusion criteria were similar to that in the North American study. Patients were randomized to six different dose regimens with an initial dosage of 200 mg degarelix or 240 mg degarelix followed by monthly maintenance dosage of degarelix 80 mg, degarelix 120 mg, or degarelix 160 mg (groups 200/80, 200/120, 200/160, 240/80, 240/120, 240/160), respectively. In all groups, a concentration of 40 mg/ml degarelix was used. Thus, the sc injected volume varied between 2 ml and 4 ml.

<table>
<thead>
<tr>
<th>Author</th>
<th>Patients</th>
<th>Study design</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gittelman$^{20}$</td>
<td>$N = 127$</td>
<td>Phase II</td>
<td>Testosterone suppression: 88% after one month, 93% and 98% (60 mg and 80 mg) after one year.</td>
</tr>
<tr>
<td>van Poppel$^{21}$</td>
<td>$N = 187$</td>
<td>Phase II</td>
<td>PSA response: Median reduction 96% after one year</td>
</tr>
<tr>
<td>Klotz$^{14}$</td>
<td>$N = 610$</td>
<td>Phase III</td>
<td>Testosterone suppression: 86% (200 mg) vs 95% (240 mg) after one month, 92% (80 mg), 96% (120 mg), 100% (160 mg) after one year.</td>
</tr>
</tbody>
</table>

Abbreviation: PSA, prostate-specific antigen.
Primary endpoint was to determine the proportion of patients with testosterone ≤0.5 ng/ml after one month and every month thereafter. Results were given for the intention-to-treat (ITT) population (n = 187 patients). Secondary endpoints were the proportion of patients with testosterone ≤0.5 ng/ml up to one year for those patients with testosterone ≤0.5 ng/ml after one month, the proportion of patients with testosterone level ≤0.5 ng/ml at day 3, times to reach 50% and 90% reduction in PSA, time to reach PSA progression (defined as a PSA increase ≥50% and at least 5 ng/ml compared to nadir on two consecutive visits at least two weeks apart), and pharmacodynamic parameters (serum testosterone, DHT, PSA, LH, and FSH over time).

There were four patients with protocol violations, 16 withdrawals due to inadequate testosterone suppression, 13 withdrawals due to adverse events, and 13 withdrawals due to other reasons. Therefore, 147/187 patients (78%) completed the trial. The median testosterone level at baseline was 4.13 ng/ml (25th–75th percentile: 3.37–5.19 ng/ml) and median PSA at baseline was 27.6 ng/ml (25th–75th percentile: 12–55 ng/ml). Tumor stages were localized in 22%, locally advanced in 32%, metastatic in 19%, and not classifiable in 22% of patients. The Gleason score was 2–4 in 19%, 5–6 in 41%, and 7–10 in 39% of cases, respectively. There were no differences between the six groups except for median PSA which was 15.2 ng/ml in the 200/80 treatment group compared to 35.3 ng/ml in the 240/120 treatment group.

No testosterone surge was observed. At day 3, 88% of patients with degarelix 200 mg as initial dose and 92% of patients with degarelix 240 mg as initial dose had testosterone levels ≤ 0.5 ng/ml (Table 1). After one month a significant higher proportion of patients who received degarelix 240 mg vs degarelix 200 mg as initial dose had a testosterone ≤0.5 ng/ml (95% vs 86%; p = 0.048). With different maintenance doses (degarelix 80 mg vs 120 mg vs 160 mg) testosterone level remained equal or below 0.5 ng/ml in 92%, 96% and 100% of patients until the end of the study. The median time to reach a PSA decline of 50% and 90% was 14 and 56 days. The only exception was the 200/80 group in whom the 90% PSA decline was reached after 84 days. After one year the median PSA reduction was 97%–98%.21

Phase III study
Recently, a randomized, open-label, three-arm phase III study to evaluate the efficacy of degarelix versus leuprolide for achieving and maintaining testosterone suppression in patients with prostate cancer over a period of one year was published.14

Men aged 18 years or older with histological confirmed adenocarcinoma of the prostate of all stages were included. Patients must have had a PSA of 2 ng/ml or more, a testosterone of 1.5 ng/ml or more, and an ECOG of 0–2. Previous or current androgen deprivation therapy was not allowed except some neoadjuvant or adjuvant androgen deprivation therapy of less than six months duration and discontinuation six months or longer ago. Patients considered for therapy with curative intention were excluded. Between February 2006 and October 2007, 807 patients were screened. Of these, 620 patients were randomized and 610 patients received the study medication. Median age was 72 years (range 50–98 years), median PSA was 19 ng/ml (25th–75th percentile: 8.7–57 ng/ml), and median testosterone was 3.93 ng/ml (25th–75th percentile: 2.89–5.1 ng/ml).

Patients were randomized to one of the three following treatment arms: Arm A: degarelix 240 mg as initial dosage (2 × 3 ml sc) followed by 80 mg (1 × 4 ml sc) monthly; Arm B: degarelix 240 mg (2 × 3 ml sc) as initial dosage followed by 160 mg (1 × 4 ml sc) monthly; Arm C: leuprolide 7.5 mg (1 × 1 ml intramuscularly [im]) monthly. A clinical flare protection with bicalutamide (1 × 50 mg per os [po]) was allowed at the discretion of the investigator.

The primary endpoint of the study was the cumulative probability of testosterone suppression ≤0.5 ng/ml from 28–364 days at monthly measurements. The trial also had 14 secondary endpoints:

- Proportion of patients with testosterone surge during the first two weeks of treatment
- Proportion of patients with testosterone levels of ≤0.5 ng/ml at day 3
- Probability of testosterone ≤0.5 ng/ml from 56–364 days
- Probability of insufficient testosterone response (defined as one or more testosterone levels ≥ 1 ng/ml or two or more testosterone measurements ≥0.5 ng/ml) from 28–364 days
- Frequency and size of testosterone increases at 255 days and/or 259 versus testosterone level at 252 days
- Serum levels testosterone, LH, FSH, and PSA over time
- Percentage change in PSA from baseline to 14–28 days
- Time to PSA failure (PSA increase ≥ 50% from nadir and ≥5 ng/ml on two consecutive occasions at least two weeks apart)
- Degarelix concentration over the first month and through levels at 308 and 336 days
- Frequency and severity of adverse events
- Clinically significant changes in laboratory values
- Changes in electrocardiogram and vital signs
- Quality of life on 0, 28, 84, 168, and 364 days
Degarelix in prostate cancer

• Hot flash frequency and hot flash score daily from study start until 354 days.

The primary endpoint (ie, testosterone levels ≥ 0.5 ng/ml from 28–364 days) was reached (in both ITT and per-protocol analyses) and thus it was demonstrated that degarelix (240/80 and 240/160) was noninferior to leuprolide (Table 1). The number of responders in the degarelix 240/80 and 240/160 as well as the leuprolide 7.5 mg group were 202/207 patients (97.2%), 199/202 patients (98.3%), and 194/201 patients (96.4%).

One of the secondary endpoints was the proportion of patients with a testosterone level ≥0.5 ng/ml at day 3. As expected, 96.1% and 95.5% of patients treated with degarelix 240/80 and 240/160 had a testosterone level ≥0.5 ng/ml at day 3. In contrast, none of the patients in the leuprolide group achieved this result. In fact, the testosterone level in the latter group increased by 65% (median level 6.3 ng/ml, p < 0.001). From days 28–364 the median testosterone levels were 0.082 ng/ml and 0.088 ng/ml in the degarelix groups and 0.078 ng/ml in the leuprolide group.

In the leuprolide group 23/201 (11%) patients received a concomitant medication with bicalutamide for clinical flare protection defined as testosterone increase >15% from baseline on any two days during the first two weeks. In this subgroup 17/23 (74%) had a testosterone surge and 144/178 (81%) of the patients in the leuprolide group who did not receive bicalutamide had a testosterone surge and none of the patients treated with degarelix had a testosterone surge.

At days 14 and 28, PSA declined from baseline by 64%/85% and 65%/83% in the 240/80 and 240/160 degarelix groups compared to 18%/68% in the leuprolide group. These differences in PSA reduction were statistically significant (p < 0.001). Insufficient response to treatment was evident in 12 patients: four and two patients (1.9% and 1%) in the degarelix 240/80 and 240/160 groups as well as six patients (3%) in the leuprolide 7.5 mg group.14

Safety

The analysis of phase I, II, and III trials demonstrates that there is no evidence for allergic reaction associated with the treatment with degarelix which was the major disadvantage for clinical use of former GNRH antagonists like abarelix.14,20–22

Results from phase II trials

In the North American phase II trial including 127 patients with prostate cancer (of whom 87 patients completed the study) adverse events occurred in 87% of patients receiving degarelix 200/80 and 81% of patients receiving degarelix 200/60 (Table 2).20 Most adverse events were mild to moderate but the exact number of mild, moderate, and severe adverse events was not given. However, 13% of patients had at least one severe adverse event. The most frequent adverse events were hot flashes

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Gittelman20 (Phase II)</th>
<th>van Poppel21 (Phase II)</th>
<th>Klotz14 (Phase III)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any adverse event (%)</td>
<td>87/81</td>
<td>57/66/75/63/73/67</td>
<td>79/83/78</td>
</tr>
<tr>
<td>Hot flash (%)</td>
<td>38/48</td>
<td>47/25/31/37/27/33</td>
<td>26/26/21</td>
</tr>
<tr>
<td>Fatigue (%)</td>
<td>16/23</td>
<td>7/3/6/10/3/7</td>
<td>3/6/6</td>
</tr>
<tr>
<td>Injection site pain (%)</td>
<td>6/8</td>
<td>3/9/0/13/9/7</td>
<td>Not given</td>
</tr>
<tr>
<td>Injection site reaction (%)</td>
<td>Not given</td>
<td>3/5/4/1</td>
<td>Not given</td>
</tr>
<tr>
<td>Weight increase (%)</td>
<td>6/6</td>
<td>0/9/13/11/9/7</td>
<td>9/11/12</td>
</tr>
<tr>
<td>Back pain (%)</td>
<td>3/9</td>
<td>7/9/6/3/6/3</td>
<td>6/6/8</td>
</tr>
<tr>
<td>Nasopharyngitis (%)</td>
<td>11/11</td>
<td>Not given</td>
<td>Not given</td>
</tr>
<tr>
<td>Dizziness (%)</td>
<td>11/9</td>
<td>Not given</td>
<td>Not given</td>
</tr>
<tr>
<td>Arthralgia (%)</td>
<td>6/6</td>
<td>Not given</td>
<td>5/3/9</td>
</tr>
<tr>
<td>Constipation (%)</td>
<td>6/6</td>
<td>Not given</td>
<td>3/5/5</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>6/6</td>
<td>Not given</td>
<td>6/7/4</td>
</tr>
<tr>
<td>Urinary tract infection (%)</td>
<td>Not given</td>
<td>7/6/6/7/6/3</td>
<td>5/1/9</td>
</tr>
<tr>
<td>ALT increase (%)</td>
<td>Not given</td>
<td>10/3/9/0/3/3</td>
<td>10/8/5</td>
</tr>
<tr>
<td>Cough (%)</td>
<td>Not given</td>
<td>7/3/6/0/3/7</td>
<td>Not given</td>
</tr>
<tr>
<td>Diarrhea (%)</td>
<td>Not given</td>
<td>3/6/0/3/7</td>
<td>Not given</td>
</tr>
<tr>
<td>Chills (%)</td>
<td>Not given</td>
<td>Not given</td>
<td>3/5/0</td>
</tr>
</tbody>
</table>

Abbreviation: ALT, alanine aminotransferase.
in 38% and 48% of patients followed by fatigue in 16% and 23% of patients. Nasopharyngitis (11% vs 11%) and dizziness (11% vs 9%) were other adverse events. Pain at the injection site was evident in 6% and 8% of patients treated with degarelix.20

In the European and South African phase II trial including 187 patients with prostate cancer (of whom 147 patients completed the study) six different dose regimens of degarelix (200/80, 200/120, 200/160, 240/80, 240/120, and 240/160) were tested.21 Adverse events occurred in 57% to 75% of patients within these groups (Table 2). Most adverse events were mild to moderate but the exact number of mild, moderate, and severe adverse events was not given. However, 11% of patients had at least one severe adverse event. Hot flashes of mild to moderate intensity were documented in 33% (range 27%–47%) of cases. Fatigue occurred in 6% (range 3%–10%) of patients and weight increase in 9% (range 0%–13%) of patients. An increase of alanine aminotransferase was measured in 9% (range 3%–10%) of patients. Pain at the injection site was evident in 10% (range 0%–13%) of patients treated with degarelix.21

In each degarelix group, five patients (2%) died compared to nine patients (4%) in the leuprolide group. None of the reported deaths was considered to be related to degarelix.20,21

Results from a phase III trial
In the randomized phase III trial adverse event were reported in 81% of 330% patients of the pooled degarelix groups and in 78% of 156% patients of the leuprolide group (Table 2).14 The intensity of all reported adverse events in the pooled degarelix group versus the leuprolide group was mild in 283 (69%) versus 138 (69%) patients, moderate in 225 (55%) versus 101 (50%) patients, and severe in 68 (17%) versus 26 (13%) patients. Serious adverse events were reported in 21 (10%) and 24 (12%) patients in the degarelix 240/80 and degarelix 240/160 groups compared to 28 (14%) patients in the leuprolide group. The number of patients terminating the study due to adverse events was comparable in the three treatment arms: 15 (7%) in the degarelix 240/80 group, 19 (9%) in the degarelix 240/160 group, and 12 (6%) in the leuprolide group.

The most frequently reported adverse events in both groups were hot flashes (26% in the pooled degarelix group vs 21% in the leuprolide group). Patients treated with degarelix reported statistically significant more injection site reactions than patients treated with leuprolide (40% in the pooled degarelix group vs <1% in the leuprolide group; p < 0.001). These injection site reactions included pain, erythema, swelling, induration, and nodule. They were the reason for discontinuation in five patients (1%) treated with degarelix although they occurred predominantly after the first injection and were documented to be mild or moderate in intensity.

In 18 patients (4%) treated with degarelix, chills were an adverse event compared to no such event in the leuprolide group (p < 0.01). Further significant differences between the treatment groups were arthralgia (4% in the pooled degarelix group vs 9% in the leuprolide group; p < 0.05) and urinary tract infections (3% in the pooled degarelix group vs 9% leuprolide group; p < 0.01).

In each degarelix group, five patients (2%) died compared to nine patients (4%) in the leuprolide group. None of the death was considered to be treatment-related.14

Conclusions
The administration of the GnRH antagonist degarelix is associated with a rapid, profound, and sustained suppression of testosterone in patients with prostate cancer. Results from the recently published randomized, open-label, three-arm phase III study showed that degarelix is not inferior to leuprolide at maintaining testosterone suppression over a one-year treatment period and degarelix was able to produce a faster testosterone suppression and PSA decline than leuprolide.14

In the last ten years, degarelix has run through various phase I and II trials and dose-finding was a major goal of these trials.22 As a result from these trials an initial dose of 240 mg seems to be the best dose to achieve a clinically relevant testosterone suppression in more than 90% of patients within three days and in more than 95% of patients after one month.14,21 A maintenance dose of 80 mg and 160 mg degarelix every four weeks resulted in a profound and sustained testosterone suppression.14,21 In December 2008, degarelix at a dose of 240 mg sc followed by 80 mg sc every month has been approved for the treatment of advanced prostate cancer by the US Food and Drug Administration (FDA) and its approval by the European Medicines Agency (EMEA) has been recommended.21 However, it is a clear disadvantage that degarelix is currently only available as a one-month formulation.

Degarelix has an immediate onset of action with no need for clinical flare protection with an antiandrogen as required in some patients treated with GnRH agonists.24 This kind of action of degarelix might offer advantages especially in patients with advanced prostate cancer and a higher risk for symptoms associated with clinical flare. Testosterone surge begins two to three days after administration of GnRH agonists.24 Theoretically, the median testosterone can increase by 100%. In the phase III trial it was demonstrated that median testosterone increased by 65%.14 This may be
associated with exacerbation of symptoms from prostate cancer. The symptoms may include bone pain, spinal cord compression, bladder outlet obstruction, cardiovascular problems, and so forth. However, there are wide discrepancies in reports of the frequency and severity of acute clinical progression or clinical flare that might result from the testosterone surge. The use of GnRH agonists for patients with metastatic prostate cancer can be associated with clinical flare in approximately 10% of the patients.\textsuperscript{24} In contrast, patients with non-metastatic prostate cancer have very little risk for clinical flare. Antiandrogen therapy reduces, but does not totally eliminate, clinical flare in patients at high risk for this scenario.\textsuperscript{24} In the phase III trial it was voluntarily allowed to give bicalutamide for prevention of clinical flare. However, only 11% patients received bicalutamide and no patient of the entire leuprolide group had documented clinical flare.\textsuperscript{14}

Abarelix (Plenaxis\textsuperscript{®}; Praecis Pharmaceuticals, Cambridge, MA, USA) was the first GnRH antagonist to be approved (in 2003) by the FDA for patients with advanced, symptomatic prostate cancer who cannot have or refuse other treatments for prostate cancer, such as other hormone treatments or surgery to remove the testicles.\textsuperscript{25} The reason for this restriction was that the administration of abarelix could be associated with acute systemic allergic reaction. In 15/1397 (1.1%) patients treated with abarelix this symptom was evident. In 14/15 patients the symptoms occurred within eight minutes of injection. In 2005, Praecis Pharmaceuticals voluntarily discontinued promotional activities relating to abarelix in the US and the sale of abarelix for patients not currently on therapy.\textsuperscript{25} However, in 2005 the drug was approved in Germany but not in other European countries. Since 2008, abarelix is available on the German market under the license of Speciality European Pharma.\textsuperscript{26} A systemic allergic reaction was not reported in any of the degarelix studies.\textsuperscript{14,20,21} Otherwise, in the randomized phase III trial 4% of the degarelix-treated patients reported chills versus none of the patients treated with leuprolide.\textsuperscript{14} These chills were neither discussed nor explained by the authors. Therefore, further reports on degarelix with long-term follow-up on efficacy and safety – especially concerning the allergic potential – are mandatory.

Also, it should be realized that 40% of patients experienced injection site reactions of degarelix compared to <1% at the im injection site of leuprolide.\textsuperscript{14} Why is the application of degarelix so painful? One explanation could be that the injected volume is rather high. In fact, 2 × 3 ml are injected to apply the initial dose of 240 mg degarelix.

If patients are diagnosed with prostate cancer the question today is: who needs androgen deprivation therapy? In a population-based cohort study of 19,271 patients older than 65 years (median age 77 years) having prostate cancer and treated with androgen deprivation therapy (7,867 patients) or conservative management (11,047 patients) were studied.\textsuperscript{27} Patients had a T1 disease in 49.8% (androgen deprivation group) compared to 64.2% (conservative management group) and the tumor was moderately and poorly differentiated in 65% and 34.2% (androgen deprivation group) compared to 83.7% and 14.2% (conservative management group). It was demonstrated that 10-year cancer-specific survival in patients receiving androgen deprivation therapy was 80.1% compared to 82.6% (Hazard ratio [HR]: 1.17, 95% confidence interval [CI]: 1.03–1.33) in patients receiving conservative management (defined as not receiving operative therapy, radiotherapy or androgen deprivation therapy within 180 during the first days from diagnosis).\textsuperscript{27} Ten-year overall survival was 30.2% (androgen deprivation group) compared to 30.3% (conservative management group) and median overall survival was 82 months in both groups. However, in patients with poorly differentiated prostate cancer it was shown that cancer specific survival was better in patients receiving androgen deprivation therapy (59.8% vs 54.3%, HR: 0.84, 95% CI: 0.7–1; p = 0.049). It is noteworthy that 75% of all patients receiving androgen deprivation therapy for a minimum of 18 months and 50% of patients for longer than 30 months.

Not only the efficacy of androgen deprivation therapy in terms of survival needs to be questioned but also possible adverse events. Androgen deprivation therapy itself is potentially associated with several adverse events. These include hot flashes, osteoporosis, loss of libido or impotence, psychological effects such as depression, memory difficulties or emotional lability, and others.\textsuperscript{28–32}

Diabetes and cardiovascular disease are especially unwanted adverse events among older patients. However, there is growing evidence that androgen deprivation therapy is associated with an increased risk of cardiovascular disease and diabetes.\textsuperscript{28} In an observational study of a population-based cohort of 73,196 patients older than 65 years (mean age 74.2 years, standard deviation 5.8 years) having prostate cancer were investigated. The endpoints incident diabetes, coronary heart disease, myocardial infarction, and sudden cardiac death occurred in 10.9%, 25.3%, 5.4%, and 4.5% of all cases. A total of 36.3% of patients received a GnRH agonist for a mean of 40% of time from diagnosis to censoring. This use of a GnRH agonist was associated with an increased risk of incident diabetes (adjusted HR: 1.44; P < 0.001), coronary heart disease (adjusted HR: 1.16; p < 0.001), myocardial infarction (adjusted HR: 1.11; P < 0.03), and sudden cardiac
death (adjusted HR: 1.16; p < 0.003). In 6.9% of patients an orchietomy was performed for androgen deprivation therapy. It is noteworthy that in these patients a greater risk for diabetes (adjusted HR: 1.34; p < 0.001) compared to no therapy was also found but this was not the case for coronary heart disease (adjusted HR 0.99; p = 0.74), myocardial infarction (adjusted HR: 0.94; p = 0.44), and sudden cardiac death (adjusted HR: 1.91; p = 0.85).

In summary, degarelix is associated with a rapid, profound, and sustained suppression of testosterone in patients with prostate cancer. Antiandrogens to prevent testosterone surge and prevent clinical flare are not required. This may reduce costs and adverse events from the antiandrogen. Thus, a GnRH antagonist rather than a GnRH agonist may be used in patients with high tumor burden and/or acute problems such as spinal cord compression. In contrast to other GnRH antagonists degarelix was not associated with systemic allergy reaction. In the phase III trial, however, two adverse events occurred more often with degarelix compared to leuproide: injection site reactions (40% vs <1%) and unexplained chills following the application degarelix (4% vs 0%). Beside adverse events there is currently no three-month formulation of degarelix available. A three-month interval for the application of GnRH agonists is convenient for the patient and currently the most often applied regimen. The phase III trial by Klotz and colleagues was not blinded and all patients “in whom androgen deprivation therapy was indicated” were included. What we don’t have for degarelix is data on cancer-specific survival and overall survival as well as any data in patients undergoing intermittent androgen deprivation therapy and complete androgen blockade. Finally, the average monthly cost of degarelix treatment is probably comparable to other hormone treatments for prostate cancer; in other words, degarelix is not cheaper. Therefore, the potential role of degarelix within a discussion about the indication for androgen deprivation therapy with regard to efficacy, adverse events, and costs remains unclear and could be limited.

Disclosure
The authors report no conflicts of interest in this work.

References


